MRI 1867
Alternative Names: MRI-1867; Zevaquenabant - Scopus BioPharmaLatest Information Update: 16 May 2025
At a glance
- Originator National Institutes of Health (USA)
- Developer National Institutes of Health (USA); Scopus BioPharma
- Class Antifibrotics; Chlorobenzenes; Pyrazoles; Skin disorder therapies; Sulfonamides
- Mechanism of Action Cannabinoid 1 receptor inverse agonists; Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic scleroderma
Most Recent Events
- 16 May 2025 Preclinical development in Systemic-scleroderma is underway in USA (PO) (Scopus Biopharma pipeline, May 2025)
- 07 Sep 2024 Pharmacodynamics data from preclinical studies in Systemic scleroderma at the 34th Annual Congress of the European Respiratory Society (ERS-2024)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Systemic-scleroderma in USA (PO)